Standard Contracts
EXHIBIT 10.5 RESEARCH AND DEVELOPMENT SERVICES AGREEMENT BY AND BETWEEN TSANN KUEN ENTERPRISE CO., LTD. AND TSAUN KUEN USA, INC.Research and Development Services Agreement • April 15th, 2004 • Eupa International Corp /Nv/ • Services-business services, nec • California
First Amendment to lbs-008 research and development services agreementResearch and Development Services Agreement • April 5th, 2022 • Belite Bio, Inc • Pharmaceutical preparations
This First Amendment to LBS-008 Research and Development Services Agreement (this “Amendment”), effective as of Feb 23, 2022 (“Effective Date”), is entered into by and between Belite Bio, Inc, a Cayman corporation, with contact office located at 5820 Oberlin Drive, Suite 101, San Diego CA, 92121 USA (“Belite Inc”) and Lin BioScience, Inc., a Taiwan corporation, located at 12F., No.68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan (“Lin Inc.”).
RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • July 1st, 2016 • ONCOSEC MEDICAL Inc • Pharmaceutical preparations • California
THIS RESEARCH AND DEVELOPMENT SERVICES AGREEMENT (“Agreement”) is being entered into as of this 6th day of March, 2015 (the “Effective Date”), by and between OncoSec Medical Incorporated, a Nevada Corporation with a principal place of business at 9810 Summers Ridge Rd., Ste. 110, San Diego, CA 92121 (the “Company”), and Rev.1 Engineering Inc., a California Corporation, having a principal place of business at 41693 Date Street, Murrieta, CA 92562 (“Rev.1”). Rev.1 and Company are at times referred to individually as a “Party” and jointly as the “Parties.”
Research and Development Services AgreementResearch and Development Services Agreement • January 11th, 2019 • Cemtrex Inc • Measuring & controlling devices, nec • New York
This Agreement is made and entered into as of this 8th day of August, 2018 by and between Vicon Industries, Inc., having a principal place of business at 135 Fell Court, Hauppauge, New York (hereinafter referred to as “Vicon” or “Parent”) and Cemtrex, Inc., having a principal place of business at 19 Engineers Lane, Farmingdale, New York 11735, and its subsidiaries. (hereinafter referred to as “Cemtrex”).
LBS-008 RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • April 5th, 2022 • Belite Bio, Inc • Pharmaceutical preparations
This Research and Development Services Agreement (this “Agreement”), effective as of July 1, 2021 (“Effective Date”), is entered into by and between Belite Bio, Inc, a Cayman corporation, with contact office located at 12F., No.68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan (“Belite Inc”) and Lin BioScience, Inc., a Taiwan corporation, located at 12F., No.68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan (“Lin Inc.”).
RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • January 26th, 2016 • ONCOSEC MEDICAL Inc • Pharmaceutical preparations • California
THIS RESEARCH AND DEVELOPMENT SERVICES AGREEMENT (“Agreement”) is being entered into as of this 6th day of March, 2015 (the “Effective Date”), by and between ONCOSEC MEDICAL INCORPORATED, a Nevada Corporation with a principal place of business at 9810 Summers Ridge Rd., Ste. 110, San Diego, CA 92121 (the “Company”), and MERLIN CSI, LLC., a California Limited Liability Company, having a principal place of business at 13135 Danielson Street, #212, Poway, CA 92064 (“Merlin”). Merlin and Company are at times referred to individually as a “Party” and jointly as the “Parties.”
AMENDMENT TO RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • May 11th, 2015 • Discovery Laboratories Inc /De/ • Biological products, (no disgnostic substances)
Effective as of May 7, 2015, Battelle Memorial Institute and Discovery Laboratories, Inc. hereby agree to amend the Research and Development Services Agreement between them dated as of June 22, 2012 (as it may have been previously amended, the “Agreement”) to reflect the revisions set forth herein. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms as set forth in the Agreement.
EXHIBIT 10(n) AMENDMENT TO RESEARCH AND DEVELOPMENT SERVICES AGREEMENT (the "Amendment") made and entered into on April 19, 2004, by and between Big Bang Technologies, Inc., a California corporation with an office at 1810 Old Oakland Road, Suite F,...Research and Development Services Agreement • May 17th, 2004 • E-Smart Technologies Inc • Computer peripheral equipment, nec
RESEARCH AND DEVELOPMENT SERVICES AGREEMENT THIS AGREEMENT, made and entered into as of this 1st day of January, 1996, by and between BIO-TECHNOLOGY GENERAL CORP., a Delaware corporation ("BTG U.S."), and BIO-TECHNOLOGY GENERAL (ISRAEL) LTD., an...Research and Development Services Agreement • March 22nd, 1999 • Bio Technology General Corp • Medicinal chemicals & botanical products • New York
AMENDMENT 2 TO RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • March 29th, 2000 • Pliant Systems Inc • Telephone & telegraph apparatus • New Jersey
RESEARCH AND DEVELOPMENT SERVICES AGREEMENT AGREEMENT NUMBER CP036763 LABOR AND MATERIALS TYPE Battelle Memorial Institute, through its Columbus Operations (BATTELLE) agrees to provide to Sanguine Corporation (CLIENT) technical/research services...Research and Development Services Agreement • April 14th, 2000 • Sanguine Corp • In vitro & in vivo diagnostic substances • Ohio
RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • June 25th, 2020 • Ontario
RECITALSResearch and Development Services Agreement • August 10th, 2000 • X10 Wireless Technology Inc • Washington
Amendment No. 1 to Research and Development Services AgreementResearch and Development Services Agreement • July 1st, 2016 • ONCOSEC MEDICAL Inc • Pharmaceutical preparations • California
This Amendment No. 1 to Research and Development Services Agreement (this “Amendment”) dated as of February 17th, 2016 (the “Amendment Date”) is entered into between OncoSec Medical Incorporated, a Nevada corporation (hereinafter, “Company”), having offices at 5820 Nancy Ridge Drive, San Diego, California 92121, and Rev.1 Engineering Inc., a California corporation (hereinafter, “Rev.1”), having offices at 41693 Date Street, Murrieta, California 92562, with respect to the following facts:
RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • August 14th, 2012 • Discovery Laboratories Inc /De/ • Biological products, (no disgnostic substances) • Delaware
This Agreement, is made and entered into on June 22, 2012 (“Effective Date”), by and between Discovery Laboratories, Inc., having a place of business at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (“Discovery”) and Battelle Memorial Institute, through its Corporate Operations, having a place of business at 505 King Avenue, Columbus, Ohio 43201 (“Battelle”) individually referred to as “Party” or collectively referred to as “Parties.”
RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • March 28th, 2006 • Ophthalmic Imaging Systems • Surgical & medical instruments & apparatus
This Research and Development Services Agreement is entered into this 1st day of January, 2004 by and between MediVision Medical Imaging Ltd., an Israeli company, with its principal place of business at 2 Hatamar St., Kenyon Hadrachim, P.O. Box 45, Upper Yokneam, 20692, Israel (“MV”) and Ophthalmic Imaging Systems, a California corporation, with its principal place of business at 221 Lathrop Way, Suite I, Sacramento, California 95815, U.S.A. (“OIS”) (each a “Party” and collectively the “Parties”).
AMENDED AND RESTATED RESEARCH AND DEVELOPMENT SERVICES AGREEMENT dated as of June 18, 2018 by and among ALX ONCOLOGY INC. and TOLLNINE, INC.Research and Development Services Agreement • June 26th, 2020 • Alx Oncology Holdings Inc • Pharmaceutical preparations • New York
This research and development services agreement (the “Agreement”) is entered into as of June 18, 2018, (the “Effective Date”) by and between Tollnine, Inc., a Delaware corporation (“Tollnine”) having an address at 1700 Owens Street, Suite 595, San Francisco, CA 94158, and ALX Oncology Inc., a Delaware corporation (“ATI”, formerly Alexo Therapeutics Inc.) having an address at 866 Malcolm Road, Suite 100, Burlingame, CA 94010. Tollnine and ATI are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • June 26th, 2020 • Alx Oncology Holdings Inc • Pharmaceutical preparations • Delaware
This research and development services agreement (the “Agreement”) is made effective as of July 1, 2020 (the “Effective Date”) by and between ALX Oncology Holdings Inc., a Delaware corporation (“ALX”) having an address at 866 Malcolm Road, Suite 100, Burlingame, California 94010, and Tallic Therapeutics, Inc. (f/k/a Tollnine, Inc.), a Delaware corporation (“Tallac”) having an address at 1700 Owens Street, Suite 595, San Francisco, California 94158. ALX and Tallac are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractResearch and Development Services Agreement • March 30th, 2004 • E-Smart Technologies Inc • Pharmaceutical preparations
Research and Development Services Agreement (the “Agreement”) dated as of January 1, 2001 (the “Effective Date”), and reduced to writing on May 29, 2003, by and between Big Bang Technologies, Inc., a California corporation with an office at 1810 Old Oakland Road, Suite F, San Jose, California 95131 (“BBT”) and e-Smart Technologies, Inc., a Nevada corporation with an office at 7225 Bermuda Road, Suite C, Las Vegas, Nevada 89119 (the “Company”). The Company and BBT are sometimes hereinafter individually referred to as a “Party” and collectively as the “Parties”.
RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • April 11th, 2011 • Brainsway Ltd. • Surgical & medical instruments & apparatus
WHEREAS, Service Provider is the fully-owned subsidiary of the Recipient; and WHEREAS, Recipient has been and is engaged in the research and development of transcranial magnetic stimulation apparatus and therapies for the treatment of depression, addictions and certain other brain deficiencies and/or malfunctions; and WHEREAS, Service Provider has been and is staffed with experienced personnel and was therefore selected to provide and co-ordinate a variety of services beneficial to Recipient, by drawing on its own resources as well as on those available from third parties; and WHEREAS, Recipient has received from the Service Provider certain R&D Services (as such term is defined below); and WHEREAS, the Service Provider declares that it had the knowledge, know-how, talents, skills, expertise and experience in order to perform the R&D Services; and WHEREAS, Service Provider has rendered to Recipient and Recipient has received the R&D Services for good and valuable consideration, all sub
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Research and Development Services Agreement • August 1st, 2016 • Indivior PLC • Pharmaceutical preparations
AMENDMENT NO. 1 TO RESEARCH AND DEVELOPMENT SERVICES AGREEMENTResearch and Development Services Agreement • January 26th, 2016 • ONCOSEC MEDICAL Inc • Pharmaceutical preparations • California
THIS AMENDMENT NO. 1 TO RESEARCH AND DEVELOPMENT SERVICES AGREEMENT (this “Amendment”) dated as of September 23, 2015 (the “Amendment Date”), is entered into between OncoSec Medical Incorporated, a Nevada corporation (hereinafter, “Company”), having offices at 9810 Summers Ridge Road, Suite 110, San Diego, California 92121, and Merlin CSI, LLC, a California limited liability company (hereinafter, “Merlin”), having offices at 13135 Danielson Street #212, Poway, California 92064, with respect to the following facts:
